TG Therapeutics and Ildong Pharmaceutical have signed a licensing deal to develop and commercialize an oncology candidate, Ublituximab, in South Korea and Southeast Asia. Under the contract, Ildong gains Ublituximab development rights in ...
Tags: TG, Ildong Pharmaceutical, Ublituximab
US-based Biomedical Advanced Research and Development Authority (BARDA) has granted $50.2m to Elusys Therapeutics for the development of investigational ETI-204 (Anthim) agent, designed for the treatment of inhalational anthrax following a ...
Medistem and Superview Biotechnology, a subsidiary of Yinhuan Holding Co from Yixing, collaborate for the development of therapeutics using antibody and stem cell technology. The collaboration will leverage proprietary stem cell lines ...
Tags: therapeutics, antibody and stem cell technology, regenerative medicine
Janssen Biotech, a Johnson & Johnson company, has executed a license and development agreement for an investigational anti-cancer agent, daratumumab (HuMax-CD38), with Genmab. Daratumumab is a human CD38 monoclonal antibody which is ...
Tags: Daratumumab License, license and development agreement, anti-cancer
The International AIDS Vaccine Initiative (IAVI), GlycoMimetics (GMI), and Glycosensors and Diagnostics (G&D) have collaborated to develop a vaccine against AIDS. The project being funded by IAVI's Innovation Fund will integrate the ...
Tags: HIV vaccine, vaccine against AIDS, carbohydrate immunogens
AbD Serotec, MorphoSys' division for research and diagnostic antibodies, is set to introduce a series of the human combinatorial antibody library (HuCAL) anti-drug antibodies supporting the development of novel antibody therapeutics. The ...
Tags: AbD Serotec, HuCAL Anti-Drug Antibodies, antibody therapeutics, MorphoSys
Antibody-drug conjugate (ADC) company, Mersana Therapeutics and Adimab have initiated a joint effort to offer integrated antibody discovery and ADC technologies. The partnership will provide pharmaceutical companies an access to Adimab's ...
Tags: Adimab, Mersana, integrated antibody discovery, ADC technologies
Merck and Ablynx have entered into a partnership to develop Nanobody candidates against a voltage gated ion channel and includes an option to elect a second target. As a part of the agreement, Ablynx will be responsible for the discovery ...
Tags: Nanobody Candidates, Nanobody technology, Ablynx Partner
Evotec has signed a strategic collaboration agreement to offer antibody discovery and development service to 4-Antibody. Evotec's high content screening combined with 4-Antibody's antibody selection approach will offer new possibilities ...
Tags: antibody discovery, 4-Antibody, human monoclonal antibodies
The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) has supported the clinical benefit of GlaxoSmithKline's raxibacumab to treat inhalational anthrax. In addition, the committee also favoured the ...
Tags: The Anti-Infective Drugs, raxibacumab anti-toxin development programme
XBiotech has received FDA fast track designation for its anti-cachexia drug Xilonix, a first-in-class True Human antibody. Xilonix blocks an inflammatory substance (IL-1a) produced by the body in response to tumor growth, which plays a ...
RayBiotech, a developer of antibody and protein array technologies, has introduced a peptoid drug candidate and diagnostic ligand discovery service program. The new service platform, which is aimed at the identification of novel ligands ...
Tags: rayBiotech, peptoid, ligand, peptoid drug candidate
Bruker has launched a new software solution, BioPharmaCompass 1.1 to encompass the complete biopharmaceutical characterization challenge, which includes glycoforms, impurities and modifications. The software allows biotech customers to ...
Tags: software solution, biopharmaceutical characterization, mass spectrometry
Genzyme, a Sanofi company, has received a refuse to file letter from the US Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of Lemtrada (alemtuzumab) as a treatment ...
Tags: Genzyme, Lemtrada marketing, FDA
American biotechnology firm XOMA has obtained orphan drug designation by the US Food & Drug Administration (FDA) for its IL-1 beta modulating antibody 'Gevokizumab', which treats non-infectious intermediate, posterior, pan-uveitis, or ...
Tags: American biotechnology, XOMA, orphan drug, FDA